Skip to main content

China's Flon Medical Material Co is considering increasing its investment in CollPlant Holdings, an Israeli producer of plant-derived human collagen, a protein vital for tissue repair.

"We have invested $2.5 million in CollPlant and we might increase this amount," Flon managing director Qian Xiaojin told Reuters during a trip to Israel.

Flon, which holds 7 percent of CollPlant, is seeking to help the Israeli company win Chinese regulatory approval and to manufacture and distribute its products in China.

"We have signed a term sheet but not a final agreement," CollPlant Chief Executive Yehiel Tal said. "Both sides want this cooperation."

The first product would be a gel to treat chronic sores, for example in patients with diabetes. CollPlant expects to obtain approval for this product in Europe this year.

"Israel is leading the world in creativity and innovation in biotech and medical devices," said Qian, who was attending a conference sponsored by Israel's Cukierman Investment House and the Wujin Economic Zone.

He said his company is also seeking technology for dental implants and air filters, with the aim of transferring technology to China to manufacture there.

Related Articles

2024 ALB China天达共和十五佳总法律顾问圆桌会议成功举办 (ZH/EN)

10月18日,2024 ALB天达共和十五佳总法律顾问圆桌会议在北京璞瑄酒店圆满举办。 本次盛会由天达共和律师事务所品牌运营总监刘思强女士主持,十五佳上榜总法及获奖代表出席了此次盛会。

功承瀛泰落子武汉,拓展华中布局(ZH/EN)

by Charlie Wu 吴卓言 |

总部位于上海的功承瀛泰律师事务所近日正式成立武汉办公室,成为该所在全国范围内的第16家分支机构。

报名开始:2025 ALB China 区域市场排名:环渤海地区 / 2025 ALB China Regional Ranking: Circum-Bohai Sea Area

ALB China 2025年首个区域市场榜单:2025 ALB China 区域市场排名:环渤海地区,现已接受提名。